



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2023-07

DATE: May 5, 2023
TO: ADAP ENROLLMENT WORKERS
SUBJECT: **ADDITION OF LENACAPAVIR (SUNLENCA) TO THE ADAP FORMULARY**

Effective April 25, 2023, Lenacapavir (Sunlenca®) has been added to the ADAP formulary.

Lenacapavir is a first-in-class human immunodeficiency virus type 1 (HIV-1) capsid inhibitor that has been developed as a long-acting injectable antiretroviral (ARV) treatment. Lenacapavir is available as an oral tablet (for lead-in dosing) and as a long-acting subcutaneous injection formulation.

Lenacapavir is administered via subcutaneous injection every six months, providing people with HIV with a very long-acting treatment option that was safe and well tolerated in clinical trials. Lenacapavir is a single ARV and must be used in combination with other ARVs. Lenacapavir has been approved for the treatment of adults with multidrug resistant HIV infection who are failing their current ARV regimen. In clinical trials, over 80 percent of participants with multidrug resistant HIV infection were able to achieve viral suppression when treated with Lenacapavir added to an optimized ARV regimen. Lenacapavir is not currently approved for use as a first-line ARV agent, but on-going clinical trials are evaluating this indication. Lenacapavir represents a significant advancement toward very long-acting HIV treatment options and can help more people achieve viral suppression. Lenacapavir received United States Food and Drug Administration approval on December 22, 2022.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](#) has been updated to reflect the addition of Lenacapavir (Sunlenca®).

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,

Sharisse Kemp, MSW
ADAP Branch Chief
California Department of Public Health